AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) has been approved in Japan for the treatment of adult patients with BRCA-mutated…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from LITESPARK-005, the first positive Phase 3 trial investigating WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. LITESPARK-005 is evaluating WELIREG for the…
CVS Health® (NYSE: CVS) today announced that it has launched Cordavis, a wholly owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce biosimilar products (an FDA approved biologic medication that is highly similar to, and has no clinically…
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV…
Biosimilars are medications that are highly similar to U.S. Food and Drug Administration (FDA)-approved reference biologics – the fastest-growing class of drugs in the U.S., bringing innovative, life-changing treatments to patients with cancer and chronic diseases. Biologics are made from living…
Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today that the Food and Drug Administration (FDA) has cleared BITT’s Investigational New Drug application (IND) for…
Immunis, Inc., a private biotech and a leading innovator in cellular secretome therapies for age and disease-related immune decline, is honored to be selected as a finalist for the “Best Emerging Technology Company” by the Octane High Tech Awards (HTA). The HTA awards…
Novartis today announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD…
Novartis today announced positive top-line results from the Phase III REMIX-1 and REMIX-2 studies evaluating remibrutinib 25 mg b.i.d., a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines1. Both…
The 2022 Kaiser Permanente Southern California Community Health Snapshot highlights our commitment to enhancing community health by addressing social factors that influence well-being and expanding access to care. In 2022, Kaiser Permanente invested $906 million in our Southern California communities. The funding…
Aetna Better Health® of Georgia, a CVS Health® company (NYSE: CVS), announced that Aetna® has provided a community investment of $40,000 to March of Dimes. The investment will contribute to a pop-up grocery market, in partnership with Goodr, serving pregnant and…
Aetna Better Health® of Kansas today announced that Aetna® has donated $30,000 to Oral Health Kansas, Inc., to help support its Pathways to Oral Health: Education Initiatives for Accessible Dental Care (Pathways) program aimed at increasing dental care for individuals with…